<DOC>
	<DOCNO>NCT02258581</DOCNO>
	<brief_summary>This study evaluate long term effect hepatitis B virus ( HBV ) treatment HBV serologic change HBV DNA level Week 144 . This registry enroll individual treat Gilead-sponsored trial chronic hepatitis B ( CHB ) .</brief_summary>
	<brief_title>Long Term Follow-up Registry Individuals Treated A Gilead-Sponsored Trial Individuals With Chronic Hepatitis B Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Key Must participate Gileadsponsored chronic hepatitis B ( CHB ) study 120 day prior Baseline ( Day 1 ) , except participant previous Gileadsponsored study number GSUS1740149 , one year last visit protocol . Must ability understand sign write informed consent form , must obtain prior initiation study procedure Must willing able comply visit schedule study requirement Must document HBV DNA &lt; 2,000 IU/mL time screen visit , shall occur later 1 year post last study visit GSUS1740149 Must document hepatitis B surface antigen ( HBsAg ) negative status anytime participation GSUS1740149 regardless ongoing HBV treatment Key Patient participate plan participate another clinical study investigational agent History clinicallysignificant illness major medical disorder may interfere followup , assessment compliance protocol Believed Study Investigator inappropriate study participation reason otherwise list Received TDF monotherapy either part GSUS1740149 Arm C ( TDF monotherapy arm ) TDF retreatment , take HBV antiviral therapy since completion GSUS1740149 Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>